Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAF265 inhibits the growth of advanced human melanoma tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2012

Su Yingjun, Vilgelm Anna E, Kelley Mark C, Hawkins Oriana E, Liu Yan, Boyd Kelli L, Kantrow Sara, Splittgerber Ryan C, Short Sarah P, Sobolik Tammy, Zaja-Milatovic Snjezana, Dahlman Kimberly Brown, Amiri Katayoun I, Jiang Aixiang, Lu Pengcheng, Shyr Yu, Stuart Darrin D, Levy Shawn, Sosman Jeffrey A, Richmond Ann

Abstract excerpt

PURPOSE: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with drug response. EXPERIMENTAL DESIGN: Advanced metastatic melanoma tumors from 34 patients were orthotopically implanted to nude mice. Tumors that grew in mice (17 of 34) were evaluated for response to RAF265 (40...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-X Protein
Share to Cyclin D1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Imidazoles

Share to Ki-67 Antigen

Share to Polo-Like Kinase 1

Share to Proto-Oncogene Proteins c-kit

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 22351689
DOI: 10.1158/1078-0432.CCR-11-1122
PMCID: PMC3724517

Genes

BRAF
BCL2
KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAF265 inhibits the growth of advanced human melanoma tumors.PMID 22351689Read ↗

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.Semantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK SignalingSemantic proximity Read ↗

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Semantic proximity Read ↗

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.Semantic proximity Read ↗

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapySemantic proximity Read ↗

B-Raf Inhibition in the Clinic: Present and FutureSemantic proximity Read ↗

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.Semantic proximity Read ↗

Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.Semantic proximity Read ↗

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironmentSemantic proximity Read ↗

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.